Elisei Rossella, Romei Cristina
Department of Endocrinology and Metabolism, University of Pisa, Lungarno Pacinotti 43 - 56126 Pisa, Italy.
Thyroid Res. 2013 Mar 14;6 Suppl 1(Suppl 1):S2. doi: 10.1186/1756-6614-6-S1-S2.
One of the most discussed and controversial issue in the management of thyroid nodules is the need to perform a routine measurement of serum Calcitonin (Ct) in all cases. The American Thyroid Association guidelines do not recommend in favor or against this procedure since they retain that there are not enough evidences that it can determine an advantage to the health outcomes of these patients. This is not the view of many European experts who met in Lisbon in 2009 at the European Thyroid Association-Cancer Research Network meeting to discuss all the still open controversial issues on the management of medullary thyroid cancer patients.This paper is focused on the routine measurement of serum Ct in all patients with thyroid nodule(s): the evidences, the rational and the benefits of this procedure are deeply analysed following the discussion that was done in Lisbon. The conclusions reached at that time are reported in detail.
甲状腺结节管理中最受讨论且具争议性的问题之一，是是否需要对所有病例常规检测血清降钙素（Ct）。美国甲状腺协会指南未推荐支持或反对该检测，因为他们认为没有足够证据表明其能给这些患者的健康结局带来益处。但许多欧洲专家并不这么看，他们于2009年在里斯本召开的欧洲甲状腺协会 - 癌症研究网络会议上，讨论了甲状腺髓样癌患者管理中所有仍存争议的问题。本文聚焦于对所有甲状腺结节患者常规检测血清Ct：依据在里斯本的讨论，深入分析了该检测的证据、原理及益处。详细报告了当时得出的结论。
